ah 6809 has been researched along with 6-ketoprostaglandin f1 alpha in 1 studies
| Studies (ah 6809) | Trials (ah 6809) | Recent Studies (post-2010) (ah 6809) | Studies (6-ketoprostaglandin f1 alpha) | Trials (6-ketoprostaglandin f1 alpha) | Recent Studies (post-2010) (6-ketoprostaglandin f1 alpha) |
|---|---|---|---|---|---|
| 163 | 1 | 49 | 4,832 | 294 | 150 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brink, C; deMontpreville, V; Gascard, JP; Norel, X; Walch, L | 1 |
1 other study(ies) available for ah 6809 and 6-ketoprostaglandin f1 alpha
| Article | Year |
|---|---|
Prostacyclin release and receptor activation: differential control of human pulmonary venous and arterial tone.
Topics: 6-Ketoprostaglandin F1 alpha; Acetylcholine; Animals; Arachidonic Acid; Blotting, Western; Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide; Dose-Response Relationship, Drug; Epoprostenol; Female; France; Humans; Indomethacin; Male; Middle Aged; Muscle, Smooth, Vascular; Nitroarginine; Pulmonary Artery; Pulmonary Veins; Receptors, Prostaglandin; Receptors, Prostaglandin E; Vasoconstriction; Vasodilation; Xanthones | 2004 |